Table 1.
Patient characteristics
| Characteristics | Patient number (n=107) | Early stage nasal type ENKTL (n=101) | ||
|---|---|---|---|---|
|
| ||||
| VIPD Group (n=34) | L/P-VIPD group (n=67) | P value | ||
| Gender | 0.146 | |||
| Male | 84 (78.5) | 29 | 48 | |
| Female | 23 (21.5) | 5 | 19 | |
| Age (years) | 1.000 | |||
| > 60 | 11 (10.3) | 3 | 6 | |
| ≤ 60 | 96 (89.7) | 31 | 61 | |
| Median (years) | 57.0 | 43.5 | 43.0 | |
| ECOG PS | 1.000 | |||
| 0-1 | 106 (99.1) | 34 | 66 | |
| 2-4 | 1 (0.9) | 0 | 1 | |
| B symptoms | 0.404 | |||
| Yes | 55 (51.4) | 15 | 36 | |
| No | 52 (48.6) | 19 | 31 | |
| IPI score | 0.685 | |||
| ≤ 1 | 97 (90.7) | 31 | 63 | |
| > 1 | 10 (9.3) | 3 | 4 | |
| LDH level | 0.066 | |||
| Elevated | 16 (15.0) | 8 | 6 | |
| Normal | 91 (85.0) | 26 | 61 | |
| Primary sites | 0.549 | |||
| Nasal cavity | 102 (95.3) | 34 | 65 | |
| nasopharynx | 5 (4.7) | 0 | 2 | |
| PINK | 0.115 | |||
| 0-1 | 96 (89.7) | 29 | 64 | |
| ≥ 2 | 11 (10.3) | 5 | 3 | |
| Ki-67 ≥ 60% | 56 (52.3) | 14 | 39 | 0.140 |
| EBER + | 99 (92.5) | 31 | 65 | 0.332 |
ECOG PS, Eastern Cooperative Oncology Group performance status; IPI, International Prognostic Index; LDH, lactate dehydrogenase; PINK, Prognostic Index of Natural Killer Lymphoma; EBER, EBV encoded RNA.